Pliant Therapeutics Announces Positive Long-Term Data from the INTEGRIS-IPF Phase 2a…
<!-- Name:DistributionId Value:8828703 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->…
Browsing Tag
Pliant Therapeutics
Pliant Therapeutics Announces Poster Presentations at the 2023 American Thoracic…
<!-- Name:DistributionId Value:8795634 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->…
Pliant Therapeutics Announces Positive DSMB Safety Review and Initiation of…
<!-- Name:DistributionId Value:8786540 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->…
Pliant Therapeutics to Participate in Upcoming Investor Events
<!-- Name:DistributionId Value:8778545 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->…
Pliant Therapeutics Announces FDA Clearance of Investigational New Drug Application …
<!-- Name:DistributionId Value:8741346 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->…
Pliant Therapeutics Announces Positive DSMB Safety Review of INTEGRIS-IPF Phase 2a…
Recent independent Data Safety Monitoring Board (DSMB) review recommended the INTEGRIS-IPF Phase 2a trial continue without modification Interim 12-week data expected in early 2023 SOUTH…
Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2022…
SOUTH SAN FRANCISCO, Calif., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel…
Pliant Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of…
SOUTH SAN FRANCISCO, Calif., July 15, 2022 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel…
Pliant Therapeutics Announces Positive Safety and Efficacy Data from Phase 2a…
PLN-74809 demonstrated a dose-dependent treatment effect on FVC and QLF versus placebo over 12 weeks of treatment PLN-74809 treatment effect was observed on top of standard of care therapy…
Pliant Therapeutics Announces Presentations at the International Liver Congress™ 2022…
SOUTH SAN FRANCISCO, Calif., June 24, 2022 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel…